Adiponectin Testing Market Size, Share & Industry Analysis, By Product Type (Assay Kits, Consumables, and Others), By Technology (ELISA, Chemiluminescent Immunoassays, Immunoturbidimetric Assays, Multiplex Bead-Based Immunoassays, and Others), By Application (Metabolic & Endocrine Disorders, Cardiovascular Disorders, Hepatic Disorders, Inflammatory & Immune Disorders, and Others), By End User (Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, and Others), and Regional Forecast, 2026–2034

The global adiponectin testing market size was valued at USD 22.9 million in 2025. The market is projected to grow from USD 24.6 million in 2026 to USD 42.7 million by 2034, exhibiting a CAGR of 7.1% during the forecast period.

Adiponectin testing involves quantitative measurement of adiponectin, an adipocyte-derived protein involved in the regulation of glucose metabolism, fatty-acid oxidation, insulin sensitivity, inflammation, and cardiovascular physiology. Testing is primarily performed on serum, plasma, cell-culture samples, and other biological specimens using ELISA, chemiluminescent immunoassays, immunoturbidimetric methods, multiplex bead-based assays, and other protein-detection technologies. Market growth is attributed to increasing research into obesity, insulin resistance, type 2 diabetes, metabolic syndrome, cardiovascular disease, hepatic disorders, and inflammatory conditions, along with expansion of biomarker-based pharmaceutical research and high-throughput proteomic analysis.

• In July 2024, Thermo Fisher Scientific Inc. completed its approximately USD 3.1 billion acquisition of Olink Holding AB, expanding its next-generation proteomics capabilities for high-throughput protein biomarker analysis.

Furthermore, Bio-Techne Corporation, Thermo Fisher Scientific Inc., Merck KGaA, Bio-Rad Laboratories, Inc., and Danaher are among the prominent companies operating in the global market.

ADIPONECTIN TESTING MARKET TRENDS

Increasing Adoption of Multiplex and Automated Protein Biomarker Testing to Transform Adiponectin Research

Researchers are increasingly shifting from single-analyte manual immunoassays toward multiplex and automated platforms capable of measuring adiponectin alongside additional metabolic, inflammatory, cardiovascular, and endocrine biomarkers. Multiplex bead-based technologies reduce sample requirements and enable simultaneous assessment of multiple proteins, while automated immunoassay platforms help improve reproducibility, throughput, and workflow efficiency. This trend is particularly important for pharmaceutical development, translational research, and large cohort studies where adiponectin is increasingly analyzed as part of broader biomarker signatures rather than as an isolated analyte.

MARKET DYNAMICS

MARKET DRIVERS

Download Free sample to learn more about this report.

Increasing Metabolic Disease and Obesity-related Biomarker Research to Drive Market Growth

Growing research into obesity, insulin resistance, diabetes, metabolic syndrome, and associated cardiovascular complications is supporting demand for adiponectin measurement. Circulating adiponectin is widely studied due to its relationship with insulin sensitivity, glucose and lipid metabolism, inflammatory activity, and cardiometabolic risk. Moreover, increasing prevalence of metabolic disorders is expanding academic and pharmaceutical interest in adipokine pathways, while drug-development programs targeting obesity and metabolic disease are increasing requirements for biomarkers capable of assessing treatment response and underlying disease biology. These factors are supporting recurring demand for assay kits, reagents, controls, and multiplex biomarker-testing platforms, further driving the global adiponectin testing market growth.

MARKET RESTRAINTS

Limited Routine Clinical Adoption and Lack of Standardized Reference Thresholds May Restrict Market Growth

Adiponectin testing remains predominantly a research-oriented biomarker assessment rather than a routine clinical diagnostic test in many healthcare systems. Concentrations may vary according to age, sex, body composition, metabolic status, assay methodology, and adiponectin isoform, complicating the establishment of universally applicable clinical thresholds. Differences between total adiponectin, high-molecular-weight adiponectin, and platform-specific measurements can further limit comparability across studies. Consequently, conventional metabolic markers such as glucose, HbA1c, lipid profiles, and insulin continue to dominate routine clinical evaluation, restricting broader adoption of standalone adiponectin testing.

MARKET OPPORTUNITIES

Integration of Adiponectin into Multi-biomarker Panels to Create Significant Growth Opportunities

Increasing emphasis on precision medicine and multi-marker disease characterization creates opportunities to incorporate adiponectin into broader cardiometabolic, inflammatory, hepatic, and drug-development biomarker panels. Combining adiponectin with insulin, leptin, inflammatory cytokines, lipid-related proteins, and other metabolic biomarkers can provide more comprehensive biological information than a single-analyte test. High-throughput multiplex platforms and proteomic technologies are making these combinations increasingly practical while reducing sample consumption.

MARKET CHALLENGES

Maintaining Cross-Platform Consistency and Analytical Reproducibility Remains Challenging

Adiponectin measurement can vary according to antibody specificity, calibration standards, sample preparation, assay sensitivity, adiponectin isoform recognition, and testing platform. Differences between ELISA, chemiluminescence, immunoturbidimetry, multiplex assays, and high-throughput proteomic technologies can create variability when results are compared across laboratories or clinical studies. Manufacturers must therefore maintain lot-to-lot consistency, analytical specificity, sensitivity, calibration stability, and matrix compatibility. Standardizing results across serum, plasma, cell-culture supernatants, and other sample types remains particularly important as adiponectin testing expands into multicenter pharmaceutical and translational studies.

Segmentation Analysis

By Product Type

High Utilization Across Academic and Pharmaceutical Research to Drive the Assay Kits Segment’s Dominance

Based on product type, the market is segmented into assay kits, consumables, and others.

The assay kits segment held the highes market share in 2025. Adiponectin assay kits provide standardized antibodies, calibrators, controls, plates, detection reagents, and protocols required for quantitative protein measurement. Their extensive use across metabolic research, drug-development studies, academic laboratories, and biomarker-validation programs supports segment’s dominance.

The consumables segment is anticipated to register a considerable CAGR of 8.2% during the forecast period.

To know how our report can help streamline your business, Speak to Analyst

By Technology

Established Analytical Performance and Broad Research Availability to Drive the ELISA Segment’s Growth

Based on technology, the market is segmented into ELISA, chemiluminescent immunoassays, immunoturbidimetric assays, multiplex bead-based immunoassays, and others.

The ELISA segment accounted for the leading market share in 2025. ELISA remains widely utilized owing to its established laboratory workflow, comparatively low equipment requirements, availability of validated commercial kits, and ability to quantitatively measure total and high-molecular-weight adiponectin in serum and plasma.

The multiplex bead-based immunoassays segment is anticipated to register a considerable CAGR of 9.6% during the forecast period.

By Application

Strong Association with Metabolic Research to Drive the Metabolic & Endocrine Disorders Segment’s Leadership

Based on application, the market is segmented into metabolic & endocrine disorders, cardiovascular disorders, hepatic disorders, inflammatory & immune disorders, and others.

The metabolic & endocrine disorders segment led the market share in 2025. Adiponectin is closely investigated in obesity, insulin resistance, type 2 diabetes, metabolic syndrome, and related metabolic abnormalities because of its role in glucose utilization, lipid metabolism, and insulin sensitivity. Increasing pharmaceutical and academic research into obesity and metabolic therapeutics therefore creates substantial demand for adiponectin assays.

The inflammatory & immune disorders segment is anticipated to rise at a considerable CAGR of 8.0% during the forecast period.

By End User

High Concentration of Biomarker Studies to Drive Academic & Research Institutes Segment’s Growth

Based on end user, the market is segmented into academic & research institutes, pharmaceutical & biotechnology companies, and others.

The academic & research institutes segment held the leading share of the global adiponectin testing market share in 2025. Universities, medical research institutions, and translational laboratories account for extensive utilization of adiponectin assays across obesity, diabetes, cardiovascular disease, hepatic disease, inflammation, and basic adipocyte-biology studies. The availability of relatively accessible ELISA and multiplex platforms further supports adoption in academic research environments.

The pharmaceutical & biotechnology companies segment is projected to register the highest CAGR of 8.6% during the forecast period.

Adiponectin Testing Market Regional Outlook

By region, the market is categorized into Europe, North America, Asia Pacific, Latin America, and the Middle East & Africa.

North America

To get more information on the regional analysis of this market, Download Free sample

North America held a substantial market share in 2024, valued at USD 8.6 million, and also maintained the leading share in 2025, with USD 9.2 million. The region's market position is supported by extensive metabolic-disease research, strong pharmaceutical and biotechnology activity, high availability of academic research funding, established proteomics infrastructure, and presence of major life-science reagent and immunoassay manufacturers.

U.S. Adiponectin Testing Market

Based on North America’s strong contribution and the U.S. dominance within the region, the U.S. market can be analytically approximated at around USD 9.1 million in 2026, accounting for roughly 37.0% of global sales.

Europe

Europe is projected to record a growth rate of 5.8% in the coming years and reach a valuation of USD 6.7 million by 2026. The region benefits from established biomedical research institutions, pharmaceutical R&D activity, large population-based cohort studies, and growing application of proteomics and biomarker analysis across cardiometabolic and inflammatory diseases.

U.K. Adiponectin Testing Market

The U.K. market size in 2026 is estimated at around USD 1.1 million, representing roughly 4.7% of global revenues.

Germany Adiponectin Testing Market

Germany’s market value is projected to reach approximately USD 1.3 million by 2026, equivalent to around 5.5% of global sales.

Asia Pacific

Asia Pacific is estimated to reach USD 6.6 million in 2026 and account for a significant share of the global market. The market in the region is growing due to rising diabetes and obesity prevalence, expanding diagnostic infrastructure, increasing metabolic disorder research, and growing healthcare investments, further supported by advancements in biomarker testing technologies.

Japan Adiponectin Testing Market

The Japan market size in 2026 is estimated at around USD 1.6 million, accounting for roughly 6.6% of global revenues.

China Adiponectin Testing Market

China’s market is projected to be one of the largest worldwide, with 2026 revenues estimated at around USD 1.9 million, representing roughly 7.7% of global sales.

India Adiponectin Testing Market

The Indian market size in 2026 is estimated at around USD 0.8 million, accounting for roughly 3.4% of global revenues.

Latin America and Middle East & Africa

Latin America and the Middle East & Africa regions are expected to witness moderate growth in this market space during the forecast period. The Latin America market is set to reach a valuation of USD 0.8 million by 2026. The market in the region is growing due to rising obesity, diabetes prevalence, and expanding diagnostic infrastructure.

Meanwhile, the Middle East & Africa market is driven by increasing metabolic disorders, healthcare investments, and growing adoption of advanced biomarker testing. In the Middle East & Africa, the GCC is set to reach a value of USD 0.2 million in 2026.

South Africa Adiponectin Testing Market

The South Africa market size is projected to reach around USD 0.1 million in 2026, representing roughly 0.6% of global revenues.

COMPETITIVE LANDSCAPE

Key Industry Players

Broad Assay Portfolios, Multiplexing Capabilities, and Biomarker Research Services to Shape Competition

The global adiponectin testing market has a semi-consolidated competitive structure, comprising prominent players such as Bio-Techne Corporation, Thermo Fisher Scientific Inc., Merck KGaA, Bio-Rad Laboratories, Inc., and Danaher. These companies maintain their market positions through broad ELISA and immunoassay portfolios, antibody development capabilities, multiplex protein-analysis technologies, established academic and pharmaceutical customer networks, and continued investment in high-throughput biomarker research.

• In July 2024, Bio-Techne Corporation participated in Spear Bio's USD 45 million Series A financing round to support development and manufacturing expansion of ultra-sensitive protein immunoassays capable of measuring biomarkers at attomolar concentrations, strengthening Bio-Techne's exposure to next-generation biomarker detection technologies.

Other notable players in the global market include Meso Scale Diagnostics, LLC, BioVendor Group, Fujirebio, Diazyme Laboratories, Inc., and FUJIFILM Wako Pure Chemical Corporation. These companies are expected to prioritize collaborations to increase their global market share during the forecast period. These companies are expected to prioritize collaborations to increase their global market share during the forecast period.

LIST OF KEY ADIPONECTIN TESTING COMPANIES PROFILED

• Bio-Techne Corporation (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)
• Merck KGaA (Germany)
• Bio-Rad Laboratories, Inc. (U.S.)
• Danaher (U.S.)
• Meso Scale Diagnostics, LLC (U.S.)
• BioVendor Group (Czech Republic)
• Fujirebio (Japan)
• Diazyme Laboratories, Inc. (U.S.)
• FUJIFILM Wako Pure Chemical Corporation (Japan)

KEY INDUSTRY DEVELOPMENTS

• December 2025: Bio-Techne Corporation launched and began first shipments of its enhanced Leo System, expanding high-throughput protein analysis with chemiluminescence and dual-channel fluorescence and enabling multiplex analysis of up to 24 targets per sample.
• June 2025: RayBiotech Life, Inc. entered a strategic collaboration with Venebio Group, LLC to combine proteomics, biomarker-discovery, and clinical-assay-development services with regulatory and clinical strategy expertise, strengthening support for pharmaceutical and diagnostic biomarker programs.
• April 2025: Quanterix Corporation introduced a new dried blood spot extraction kit for its Simoa assay portfolio, expanding minimally invasive sample preparation for ultrasensitive protein biomarker analysis and supporting broader biomarker research accessibility.
• January 2024: Standard BioTools Inc. completed its merger with SomaLogic, Inc., creating a broader multi-omics and proteomics platform with capabilities for high-throughput protein biomarker discovery across metabolic, cardiovascular, and pharmaceutical research.
• December 2023: Danaher Corporation completed its acquisition of Abcam plc, adding Abcam's antibodies, ELISA kits, and protein-research reagents to Danaher's life-science portfolio and strengthening its presence in biomarker research tools.

REPORT COVERAGE

The global adiponectin testing market analysis includes a comprehensive study of the market size & forecast by all the market segments included in the report. It includes details on the market dynamics and market trends expected to drive the market over the forecast period. It provides information on key aspects, including an overview of technological advancements, the regulatory environment, and product launches. Additionally, it details partnerships, mergers & acquisitions, as well as key industry developments and investments by key regions. The global market research report also provides a in-depth competitive landscape analysis, including information on the market share and profiles of key operating players.

Request for Customization   to gain extensive market insights.

Report Scope & Segmentation

Research Methodology

1. Bottom Up Approaches

Approach 1:  Country-Level Adiponectin Test Utilization & Spending Analysis

• Estimate country-level adiponectin testing volumes across academic institutes, pharmaceutical & biotechnology companies, CROs, and other research users.
• Assess national research expenditure, metabolic-disease research activity, obesity and diabetes research funding, pharmaceutical R&D, and biomarker-study activity.
• Estimate adiponectin assay utilization across ELISA, chemiluminescent immunoassays, immunoturbidimetric assays, multiplex bead-based platforms, and other technologies.
• Separate adiponectin-specific testing expenditure from broader cytokine, adipokine, insulin, leptin, inflammatory-marker, and general proteomic testing.
• Evaluate annual assay-kit usage according to research project volume, sample number, repeat-testing requirements, and assay capacity.
• Estimate country-level market values using:
• Research Samples Tested × Adiponectin Testing Penetration × Tests per Sample × Manufacturer Selling Price
• Aggregate country-level estimates into regional and global totals.

Approach 2:  Assay-kit Volume, Consumables & ASP Analysis

• Estimate annual unit demand for adiponectin assay kits by technology and end user.
• Determine average number of tests per kit and annual kit utilization across academic and pharmaceutical laboratories.
• Estimate recurring demand for assay consumables, controls, calibrators, buffers, plates, beads, cartridges, and other qualifying components.
• Assess manufacturer ASPs according to technology, test capacity, species reactivity, sensitivity, sample type, automation level, and geographic market.
• Separate single-analyte adiponectin testing from multiplex panels in which adiponectin is one of several biomarkers.
• Allocate a proportional value to adiponectin within multiplex panels to prevent overestimation.
• Cross-check calculated market values against distributor prices, manufacturer catalogs, procurement records, and research laboratory expenditure.

Approach 3:  Secondary & Institutional Data Cross-Check

• Validate assumptions using NIH, WHO, OECD, World Bank, national research agencies, diabetes associations, obesity-research organizations, clinical-trial databases, and peer-reviewed literature.
• Track annual scientific publications involving adiponectin, ADIPOQ, adipokines, insulin resistance, obesity, metabolic syndrome, cardiovascular disease, hepatic disorders, and inflammatory conditions.
• Review ClinicalTrials.gov and other trial registries for studies incorporating adiponectin as a biomarker.
• Track product introductions, assay-menu expansions, proteomic platform developments, mergers, acquisitions, partnerships, and research collaborations.
• Use official company websites, annual reports, investor presentations, product catalogs, assay validation documents, and technical datasheets.
• Exclude third-party syndicated market-research estimates as primary evidence for final market size and segment shares.

2. Top Down Approaches

Approach 1: Revenue & Market Share Analysis of Major Manufacturers

• Estimate adiponectin-testing-attributable revenues of major manufacturers and suppliers.
• Analyze companies including:
• Bio-Techne Corporation
• Thermo Fisher Scientific
• Merck KGaA
• Abcam
• RayBiotech
• Diazyme Laboratories
• Immunodiagnostics Limited
• Diagnostics Biochem Canada
• Cayman Chemical
• OriGene Technologies
• Other regional suppliers
• Isolate revenues attributable to adiponectin ELISA kits, immunoturbidimetric assays, multiplex panels, cartridges, controls, calibrators, and associated consumables.
• Exclude unrelated immunoassays, general proteomics services, instruments not attributable to adiponectin testing, antibodies sold solely for western blotting or immunohistochemistry, and unrelated diagnostic products.
• Estimate undisclosed adiponectin revenues using product availability, pricing, academic citation counts, distribution coverage, and share of metabolic-research portfolios.
• Compare aggregated manufacturer revenues with bottom-up research-utilization estimates.

Approach 2:  Triangulation, Validation and Forecast Modeling

• Compare manufacturer-derived revenues with:
• Country-level research spending
• Assay-kit unit demand
• Consumable consumption
• Academic publication activity
• Pharmaceutical biomarker programs
• Clinical-trial utilization
• ASP analysis
• Multiplex panel adoption
• Proteomics platform utilization
• Investigate material differences between supply-side and demand-side estimates.
• Adjust for double counting where assay kits are sold through distributors or incorporated into contract research services.
• Forecast individual country markets before aggregating into regional and global estimates.
• Develop forecasts using:
• Obesity and diabetes research growth
• Metabolic-drug development activity
• Pharmaceutical R&D expenditure
• Biomarker-validation studies
• Multiplex immunoassay adoption
• High-throughput proteomics adoption
• Research funding
• Academic publication trends
• Assay pricing
• Geographic expansion
• Product launches
• Apply conservative, base-case, and higher-growth scenarios .

3. List of Key Sources

• Company annual reports
• SEC and regulatory filings
• Investor presentations
• Company product catalogs
• Technical datasheets
• Assay instructions for use
• Manufacturer pricing documents
• Distributor catalogs
• NIH
• ClinicalTrials.gov
• PubMed
• WHO
• OECD
• World Bank
• National research agencies
• Diabetes research organizations
• Obesity and metabolic-disease associations
• Pharmaceutical R&D databases
• Academic publication databases
• Proteomics databases
• Official company press releases
• Acquisition announcements
• Partnership announcements
• Assay launch announcements
• Biomarker-validation publications

4. Primary Interviews

Supply Side Interviews: 60%

• Key respondents: adiponectin assay-kit manufacturers, immunoassay companies, antibody manufacturers, multiplex platform suppliers, proteomics companies, reagent suppliers, distributors, product managers, R&D executives, biomarker scientists, regulatory professionals, regional sales executives, and business-development managers.
• Validate adiponectin assay-kit revenues.
• Validate annual kit shipments.
• Validate consumables sales.
• Validate ELISA versus multiplex technology mix.
• Validate manufacturer ASPs.
• Validate regional sales.
• Validate academic versus pharmaceutical customer mix.
• Validate assay sensitivity, sample requirements, and product positioning.

Demand Side Interviews: 40%

• Key Respondents: academic researchers, endocrinology researchers, metabolic-disease scientists, cardiovascular researchers, hepatology researchers, immunology researchers, pharmaceutical biomarker scientists, biotechnology companies, CRO laboratories, and translational-research professionals.
• Validate adiponectin assay utilization.
• Validate annual research sample volumes.
• Validate assay-kit purchasing frequency.
• Validate ELISA versus multiplex preferences.
• Validate biomarker-panel design.
• Validate sample-type utilization.
• Validate pharmaceutical and academic demand.
• Validate future adoption of automated, multiplex, and high-throughput adiponectin testing .